ROCKVILLE, Md., April 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health...
The National Institute for Health and Clinical Excellence (NICE) has today published final guidance recommending the use of topotecan in combination with cisplatin as a treatment option for women with recurrent or stage IVB cervical cancer who have not previously received cisplatin.
Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for recurrent and stage...
The National Institute for Health and Clinical Excellence has granted patients with small cell lung cancer restricted access to GlaxoSmithKline’s oncology drug Hycamtin on the National Health Service.
The cost regulator has published a Final Appraisal Determination recommending use of the drug in patients suffering a relapse of the disease but only when retreatment with the first-line therapy “is not considered appropriate”...
Trading Markets.com
Mon. September 14, 2009; Posted: 08:59 AM
Sep 14, 2009 (Datamonitor via COMTEX) The UK's National Institute of Health and Clinical Excellence has proposed that GlaxoSmithKline's Hycamtin be used in combination with cisplatin in women with stage IVb cervical cancer only if they have not previously received cisplatin. The health authority's decision is likely to restrict Hycamtin's use further and limit the number of treatment options available for advanced...
Novel Delivery of Topotecan Shows Promise for Extending Survival Time in Patients with Malignant Gliomas
Released: Fri 24-Apr-2009, 13:00 ET
Embargo expired: Mon 04-May-2009, 06:30 ET
Newswise — Malignant gliomas are generally fatal tumors that are highly resistant to treatment. Glioblastoma multiforme (GBM) is the most invasive type of glial tumor. These tumors tend to grow rapidly, spread to other tissue, and have a poor prognosis. One of the biggest challenges...
